BY CHRISTIAN BUNDGAARD
-
Catalent sells factory and headquarters in midst of Novo acquisition
Novo Holdings does not want to discuss the offer.
-
Novo Nordisk: US miscalculates costs from Medicare coverage of obesity drugs
A record from the United States Congressional Budget plan Workplace jobs enormous boosts in Medicare prices, however according to Novo Nordisk, the estimation is incorrect.
-
Leo Pharma sets new climate goal: Net zero emissions by 2050
The brand-new objective begins top of Leo Pharma’s various other aspirations in the location.
-
Eli Lilly hires first chief AI officer
The brand new rent involves the function from a dean place and has a PhD in machine studying.
-
Zealand Pharma CEO on new FDA hurdle: “Insanely annoying situation”
The timing of the examination of dasiglucagon has actually been unfortunate for Zealand Pharma, which currently needs to delay obtaining the medicine to individuals by a couple of …
-
Contact for years: How Pharmacosmos secured US cancer company in triple-digit million-dollar deal
The ultimate worth for G1 Therapeutics was over half a billion kroner greater than Pharmacosmo’s first bid.
-
BII sets new target after several companies reach clinical phase
The previous 2030 target is no more an objective, yet a truth.
-
Consumer watchdog criticizes Bavarian Nordic for high vaccine prices
Bavarian Nordic has actually challenged the objection.
-
Contact for years: How Pharmacosmos secured US cancer company in triple-digit million-dollar deal
The final price for G1 Therapeutics was over half a billion kroner more than Pharmacosmo’s first bid.
-
13 years of work culminated on Friday for Orphazyme founders: “It was, I think, one of the best days of my life”
” There are extremely couple of individuals worldwide that ever before reach experience that what you have actually dealt with, initially as a PhD trainee and afterwards in y…
